(E)-4-((4-(dimethylamino)phenyl)diazenyl)benzene-1-sulfonyl chloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 偶氮苯
• 英文名称: (E)-4-((4-(dimethylamino)phenyl)diazenyl)benzene-1-sulfonyl chloride
• 英文别名: 4-(4-dimethylaminophenyl)azo-benzenesulfonyl chloride；4-[[4-(dimethylamino)phenyl]azo]-benzenesulfonyl chloride；4'-(dimethylamino)-azobenzene-4-sulfonic acid chloride；4-(4-dimethylamino-phenylazo)benzenesulfonyl chloride；4-N,N-dimethylaminoazobenzene-4'-sulfonyl chloride；4-(Dimethylamino)azobenzol-4'-sulfonsaeurechlorid
• 化学式: C₁₄H₁₄ClN₃O₂S
• 分子量: 323.803
• InChiKey: VTVWTPGLLAELLI-WUKNDPDISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  62.1
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  (E)-4-((4-(dimethylamino)phenyl)diazenyl)benzene-1-sulfonyl chloride 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 2'-deoxy-N3-[6-(4-(dimethylamino)azobenzene-4'-sulfonamido)]hex-1-yl-5'-O-(4,4'-dimethoxytrityl)uridine
  参考文献：
  名称：

  寡核苷酸衍生化的多功能策略。将镧系元素（III）螯合物引入寡核苷酸。

  摘要：

  [反应：见正文]通过2'-脱氧-5'-O-（4,4'-二甲氧基三苯甲基）尿苷与结构中含有共轭基团的伯醇之间的Mitsunobu反应合成了新型核苷亚磷酰胺嵌段（官能团，有机染料或镧系元素（III）螯合物的前体），然后进行磷酸化。它们以标准方式用于机器辅助DNA合成。略加修饰的脱保护程序用于制备拴在镧系元素（III）螯合物上的寡核苷酸缀合物。对于后一种应用，还合成了一个非核苷嵌段。

  DOI：

  10.1021/ol016093m
• 作为产物：
  描述：

  methyl orange 生成 (E)-4-((4-(dimethylamino)phenyl)diazenyl)benzene-1-sulfonyl chloride
  参考文献：
  名称：

  WOLSKI, T.;GRODZICKI, Z.;GOLKIEWICZ, W.;SOCZEWINSKI, E.

  摘要：

  DOI：

文献信息

• SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES
  申请人：AM Chemicals LLC

  公开号：US20180016232A1

  公开（公告）日：2018-01-18

  Novel non-nucleoside solid supports and phosphoramidite building blocks for preparation of synthetic oligonucleotides containing at least one non-nucleosidic moiety conjugated to a ligand of practical interest and synthetic processes for making the same are disclosed. Furthermore, oligomeric compounds are prepared using said solid supports and phosphoramidite building blocks, preferably followed by removal of protecting groups to provide oligonucleotides conjugated to ligands of interest.

  揭示了用于制备含有至少一个非核苷酸基团与实用兴趣配体共轭的合成寡核苷酸的新型非核苷酸固相支持体和磷酰胺酸酯构建块，以及制备这些固相支持体和磷酰胺酸酯构建块的合成过程。此外，使用所述固相支持体和磷酰胺酸酯构建块制备寡聚合物化合物，最好是在去除保护基的情况下，以提供与感兴趣的配体共轭的寡核苷酸。
• 3-ARYL PROPIOLONITRILE COMPOUNDS FOR THIOL LABELING
  申请人：UNIVERSITE DE STRASBOURG

  公开号：US20160145199A1

  公开（公告）日：2016-05-26

  The present invention relates to a process for labeling compounds comprising thiol moieties with 3-arylpropiolonitrile compounds, to 3-arylpropiolonitrile compounds substituted with tag moieties and to specific 3-arylpropiolonitrile linkers.

  本发明涉及一种将含硫醇基团的化合物用3-芳基丙炔腈化合物标记的方法，以及用标记基团取代的3-芳基丙炔腈化合物和特定的3-芳基丙炔腈连接剂。
• [EN] NOVEL GLUTAMINE ANTAGONISTS AND USES THEREOF<br/>[FR] NOUVEAUX ANTAGONISTES DE LA GLUTAMINE ET LEURS UTILISATIONS
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2019071110A1

  公开（公告）日：2019-04-11

  Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof. Also disclosed are methods of enhancing the effects of an immune checkpoint inhibitor, enabling a subject to respond to an immune checkpoint inhibitor, or enabling the toxicity or the dose or number of treatments with an immune checkpoint inhibitor to be reduced, comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof, and an immune checkpoint inhibitor. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder that is refractory to checkpoint inhibitor therapy, the method comprising administering to a subject in need thereof, and having the refractory disease or disorder, a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof.

  谷氨酰胺拮抗剂及其用于治疗肿瘤、免疫和神经系统疾病的方法已被披露。还披露了治疗肿瘤、免疫、传染性或神经系统疾病或紊乱的方法，该方法包括向需要治疗的受试者施用本公开的谷氨酰胺拮抗剂或其药物组成的治疗有效量。还披露了增强免疫检查点抑制剂效果的方法，使受试者对免疫检查点抑制剂产生反应，或减少免疫检查点抑制剂的毒性或剂量或治疗次数的方法，包括向需要治疗的受试者施用本公开的谷氨酰胺拮抗剂或其药物组成的治疗有效量，以及免疫检查点抑制剂。还披露了治疗对检查点抑制剂疗法无效的肿瘤、免疫、传染性或神经系统疾病或紊乱的方法，该方法包括向需要治疗的受试者施用本公开的谷氨酰胺拮抗剂或其药物组成的治疗有效量。
• [EN] QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION<br/>[FR] AMPLIFICATION DU SIGNAL D'ANALOGUES DE QUINONEMÉTHIDES
  申请人：VENTANA MED SYST INC

  公开号：WO2015124703A1

  公开（公告）日：2015-08-27

  Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.

  本文披露了一种新型的醌甲烯类似物前体，以及使用该前体的方法和套件的实施例，用于检测生物样本中的一个或多个靶标。检测方法包括将样本与检测探针接触，然后将样本与包含酶的标记共轭物接触。酶与包含可检测标记的醌甲烯类似物前体相互作用，形成具有可检测标记的反应性醌甲烯类似物，该类似物与生物样本中的靶标近距离或直接结合。然后检测可检测标记。在某些实施例中，通过多个醌甲烯类似物前体与不同酶相互作用，无需酶去活化步骤即可检测多个靶标。
• [EN] 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES<br/>[FR] DÉRIVÉS DE 2'-O-AMINOOXYMÉTHYL NUCLÉOSIDE POUR L'UTILISATION DANS LA SYNTHÈSE ET LA MODIFICATION DE NUCLÉOSIDES, NUCLÉOTIDES ET OLIGONUCLÉOTIDES
  申请人：US HEALTH

  公开号：WO2012138530A1

  公开（公告）日：2012-10-11

  Disclosed are O-protected compounds of the formula (I):wherein B is an optionally protected nucleobase, and R1-R3 are as described herein, a method of preparing such compounds, and a method of preparing oligonucleotides such as RNA starting from such compounds. The O-protected compounds have one or more advantages, for example, the 2'-O-protected compound is stable during the various reaction steps involved in oligonucleotide synthesis; the protecting group can be easily removed after the synthesis of the oligonucleotide, for example, by reaction with tetrabutylammonium fluoride; and/or the O-protected groups do not generate DNA/RNA alkylating side products, which have been reported during removal of 2'-O-(2-cyanoethyl)oxymethyl or 2'-O-[2-(4-tolylsulfonyl)ethoxymethyl groups under similar conditions.

  揭示了公式（I）中的O-保护化合物：其中B是可选择保护的核碱基，R1-R3如本文所述，一种制备这种化合物的方法，以及一种从这种化合物开始制备寡核苷酸（如RNA）的方法。这些O-保护化合物具有一个或多个优点，例如，2'-O-保护化合物在寡核苷酸合成中涉及的各种反应步骤中是稳定的；保护基在寡核苷酸合成后可以轻松去除，例如，通过与四丁基氟化铵反应；和/或O-保护基在类似条件下去除2'-O-(2-氰乙基)氧甲基或2'-O-[2-(4-甲苯磺酰基)乙氧甲基基团时不会产生已报道的DNA/RNA烷基化副产物。

表征谱图